author-photo

Alice B. Gottlieb

Tufts Medical Center
Icahn School of Medicine at Mount Sinai
New York Medical College

750

Papers

34798

Citations

Citation Trend

Filter By

Papers (749) Sort By

Journal Conference Others

A clinical perspective on risk factors and signs of subclinical and early psoriatic arthritis among patients with psoriasis.

2021 Journal of Dermatological Treatment
- Alice B. Gottlieb
- Joseph F. Merola
Show All
- Source
- Cite
- Save
Citations (1)
27141 Patient-reported psoriasis symptoms stratified by sex and level of skin clearance in clinical trials of brodalumab

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
25800 Bimekizumab for the treatment of moderate to severe psoriasis of the scalp: Post hoc analysis from the BE SURE phase 3 trial

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis.

2021 Arthritis & Rheumatism
Show All
- Source
- Cite
- Save
Citations (1)
Clinical Implications and Predictive Values of Early PASI Responses to Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis.

2021 Journal of Dermatological Treatment
Show All
- Source
- Cite
- Save
Citations (0)
P189 Comparison of secukinumab versus adalimumab efficacy on skin outcomes in psoriatic arthritis: 52-week results from the EXCEED study

2021 Rheumatology
Show All
- Source
- Cite
- Save
Citations (0)
25799 Efficacy and safety of ixekizumab in patients with moderate-to-severe plaque psoriasis with and without psoriatic arthritis at baseline: Results from UNCOVER studies through 5 years

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
25792 Improvements in BSA associate with improvements in itch and quality of life in patients with moderate-to-severe psoriasis treated with ixekizumab or guselkumab through 24 weeks

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR.

2021 Drug Safety
Show All
- Source
- Cite
- Save
Citations (0)
27529 Safety of guselkumab in patients with psoriatic arthritis through 1 year: Pooled findings from DISCOVER-1 and DISCOVER-2 phase 3 trials

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)